Supplementary Figures
: (left) SDS-PAGE analysis of reaction (30 minutes at 37 °C) between Ub-Prg (0.5 mg/mL) and UCHL3 (0.5 mg/mL) in presence of various reducing agents at 10 mM and 1 mM concentrations. The reaction was also performed in presence of EDTA, Propargylamine and N-glycinylpropargylamide at 10 mM, 1 mM and 0.1 mM final concentrations. None of these reagents influenced the reaction at the indicated concentrations. (right) Inhibition of reaction between UCHL3 and Ub-Prg by general cysteine alkylating agents. Reactions were pre-incubated with inhibitor for 30 minutes at 37ºC prior to addition of Ub-Prg. After 30 minutes at 37ºC SDS-PAGE loading buffer was added to stop the reaction.
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Figure S2: Stoichiometry of the reaction between Ub-Prg and UCHL3. UCHL3 (50 µM) was incubated with a serial dilution of Ub-Prg and reacted 30 minutes at 37 °C. The reaction went to completion at approximately 1:1 ratios.
Figure S3:
Comparison of reaction kinetics of Ub-Prg and Ub-VME. UCHL3 was incubated with either of the DUB-activity probes and samples were taken at the indicated timepoints. Both reactions did not progress after 1 minute.
Figure S4:
Test of cleavage conditions of the Ub-Prg•UCHL3 covalent complex. The complex is stable for at least three hours to mild acids and only cleaved by strong acids, such as hydrochloric and sulfuric acid and trifluoroacetic acid.
Figure S5: A) Structure of NONOates used in the reaction and their corresponding half-lives at pH 7.4; diethylenetriamine NONOate (1) has a half-life of approx. 20 hours; dipropylenetriamine NONOate (2) has a halflife of approx. 3 hours; diethylNONOate (3) has a half-life of < 5 minutes; B) Addition of each of these NONOates to the reaction between UCHL3 and Ub-Prg. Ub-Prg was pre-incubated with the NONOates for 30 minutes at 37 °C prior to the addition of the other reagent. Comparison of DUB labeling between TMR-Ub-VME and TMR-Ub-Prg, the third and sixth lane have been pretreated with unlabeled Ub-Prg and Ub-VME respectively. DUBs are subsequently labeled with TMR-Ub-VME and TMR-UbPrg respectively to visualize the DUBs that were not depleted by the unlabeled probe. Bottom: same gel at higher exposure showing additional band 5 more clearly.
Figure S11: Overview of Click-on/Click-off pull down. Ub-Prg can be directly immobilized onto Sepharose resin. The immobilized probe is incubated with a mixture of DUBs and non-DUBs (i.e. lysate). Cysteine DUBs will selectively react with immobilized Ub-Prg, resulting in their covalent attachment. Stringent washing removes unbound non-DUBs. After purification, the DUBs can be cleaved off under radical conditions for retrieval of active DUBs or by treatment with trifluoroacetic acid for MS-profiling. Figure S12 : (left) Pulldown of UCHL3 from a mixture of UCHL3 and BSA. Increasing amounts of Ub-Prg-resin resulted in the increased removal of UCHL3 from the mixture. Immobilized ubiquitin did not result in any pulldown of UCHL3; (right) the immobilized UCHL3 was released by incubation of the resin with 5% TFA in water. After resolubilization in SDS-PAGE sample buffer the released protein was observed. Figure S17: Synthesis and application of a caspase-1 probes IL-1β 102-116 -Prg and IL-1β 92-116 -Prg: (A) Aspartic acid was converted the aspartic acid aldehyde, which was converted to the alkyne in one step using the Bestmann-Ohira reagent 1 . It was then incorporated at the C-terminus of a Cy5-labeled peptide corresponding to C-terminal 34 amino acids or C-terminal 23 amino acids of IL-1β propeptide; (B) These peptides were then incubated with recombinant activated caspase-1 2 in presence or absence of the cysteine alkylating agent iodoacetamide (IAc). Reaction between the probes and caspase-1 could be observed only in absence of this alkylating agent; (C) activated caspase-1 was doped into U937 lysate and subsequently labeled with Cy5-IL-1β 92-116 -Prg. It was the only band to be found and binding could again be abolished by pre-incubation of the lysate with iodoacetamide. UBA1 (UBE1) was expressed and purified as described 3 , USP7-CD was a kind gift from Alex Faesen and SENP6 was a kind gift from Ron Hay. Papain was obtained from Sigma-Aldrich. Recombinant caspase-1 was purchased from Enzo Life Sciences (catalog number: BML-SE168).
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Synthesis of 2-butynylamine
2-butynylamine•HCl was obtained following a literature procedure by Nishizawa et al. 4 .
Synthesis of 5-hexynylamine
5-hexyn-1-ol (10.2 mmol, 1.0 g / 890 μL), triphenylphosphine (11.7 mmol, 3.06 g) and N-Boc-phosphoramidic acid diethyl ester (10.2 mmol, 2.58 g, TCI B1734) were dissolved in 40 mL anhydrous THF. The reaction mixture was flushed with argon before cooling down to 0 o C. Diisopropyl azodicarboxylate (11.7 mmol, 2,3 mL) was added dropwise to the reaction over 10 minutes. The reaction was allowed to warm to room temperature and stirred for 4 hours. After concentration in vacuo the resulting product was dissolved in 50 mL benzene. Dry HCl gas was bubbled through the stirred benzene solution for 1 hour. The resulting solution was sealed and allowed to stir overnight. A white precipitate was formed. Benzene was removed under reduced pressure and the white precipitate was washed with Et 2 O. The precipitate was filtered and washed twice with Et 2 O and dried. The resulting product was used without further purification. NMR was in accordance with literature values 5 
Production of recombinant UCHL3
Recombinant UCHL3 was expressed and purified as described previously 6 . Analysis by LC-MS showed a single form of the purified protein: Ubiquitin 1-75 was synthesized as described previously 3 : Ubiquitin-75 was synthesized on TentaGel® R TRT-Gly Fmoc (Rapp Polymere GmbH; RA1213), a preloaded trityl resin. After synthesis the identity was confirmed by LC-MS after treating a small amount of resin with TFA cleavage cocktail (92,5% TFA, 5% H 2 O, 2,5% Triisopropylsilane) and precipitation of the cleaved product in cold diethylether:pentane (3/1). The N-terminal Fmoc-group was removed by treatment with 20% piperidine in N-Methyl-2-pyrrolidone (NMP) (3 x 10 mL, 10 minute incubation). After treatment the resin was washed 3 times with NMP followed by 3 washes with methylenechloride (DCM) to remove traces of NMP. The resin was then incubated for 30 minutes with 2 bed volumes of hexafluoroisopropanol:DCM mixture (2:8) to afford a DCM soluble protected ubiquitin 1-75 polypeptide. After evaporation of solvent under reduced pressure, the solid was dissolved in DCM (5 mL), and 65 mg PyBOP (125 µmol, 5 eq), 17.4 µL triethylamine (125 µmol, 5 eq.) and 16 µL propargylamine (250 µmol, 10 eq) were added. The reaction mixture was stirred at room temperature overnight before concentration in vacuo. Excess propargylamine was removed first by co-evaporation with DCM and toluene followed by dissolution of the protected Ub-Prg in DCM and extraction with 1M KHSO 4 (4 times) before drying the organic layer of sodium sulfate and concentration in vacuo. The resulting off-white solid was dried overnight under high vacuum.
The protected Ub-Prg was deprotected using TFA cleavage mixture (95% TFA, 3% H2O, 2% triisopropylsilane) for 2.5 hours. The deprotected polypeptide was precipitated in cold diethyl ether/pentane (3:1). The precipitated crude product was collected by centrifugation (1000 g, 5 minutes) and washed 3x with cold diethyl ether and further purified as described in the 'general purification procedure' below.
N-terminal TMR-modified Ub-Prg (TMR-Ub-Prg)
5-Carboxy-Tetramethylrhodamine (TMR, 56 mg, 125 µmol, 5 eq) was preactivated in anhydrous DMF by the addition of PyBOP (65 mg, 125 µmol, 5 eq) and triethylamine (17.5 µL, 125 µmol, 5eq). The reaction was incubated for 5 minutes prior to the addition of protected Ub-propargyl to the reaction mixture (25 µmol). After reacting overnight the solvent was removed under reduced pressure and the resulting deep purple solid was deprotected using TFA cleavage conditions as described for Ub-Prg.
General Purification Procedure of Ub-Prg and mutants
The crude Ub derivatives were folded by taking it first up in a minimal amount of warm DMSO and then diluting the DMSO solution with 50 mM NaOAc pH 4.5 -the final DMSO concentration is kept as low as possible (2 -10%). Next, the folded peptide was purified by cation exchange chromatography using Workbeads 40S (Cation Exchange) material with a 0 -1 M NaCl gradient in 50 mM NaOAc pH 4.5. Pure (>90%) fractions, as indicated by LC-MS, were pooled and injected on a RP-HPLC. Phenomenex Jupiter 5µm C18 300A (250x30) These were synthesized at 6.25 µmol scale using the same procedure as for Ub-Prg using propylamine, allylamine and 2-butynylamine•HCl instead of propargylamine. To the reaction with 2-butynylamine•HCl and 5-hexynylamine•HCl an additional 15 eq of triethylamine were added. 
Figure MM2: Analysis of Ub-Prg (top) chromatograms, UV 280, DAD and TIC (middle) spectrum of product (bottom) Deconvoluted mass of product
Ub-Prg
Experimental: Synthesis of (S)-tert-butyl 3-aminopent-4-ynoate hydrochloride. (S)-tert-butyl 3-((tert-butoxycarbonyl)amino)-4-hydroxybutanoate (5) 7
Boc-L-Asp(tBu)-OH DCHA salt (4, 18.8 g, 40.0 mmol) was dissolved in THF (40 mL) and cooled to -10 °C. Nmethylmorpholine (4.62 mL, 42.0 mmol) was added and the reaction was stirred for 5 minutes. Isobutyl chloroformate (5.45 mL, 42.0 mmol) was added drop wise over a period of 10 minutes and the reaction was stirred for another 30 minutes. Next, the solids were removed by filtration over a pad of Celite and the filtrate was collected in a cooled (0 °C) solution of NaBH 4 (3.0 g, 70.0 mmol) in water (80 mL). The reaction was stirred for 1 hour at 0 °C and then allowed to warm to room temperature. The solution was diluted with 80 mL EtOAc and extracted with 1 M HCl, water, saturated NaHCO 3 and brine. The organic layer was dried over MgSO 4 and concentrated under reduced pressure. The title compound was obtained after purification by column chromatography (20% → 33% EtOAc/hexane) as a colorless oil (yield: 4.7 g, 17.0 mmol, 42%). The spectroscopic data corresponded with those reported in literature 7 .
(S)-tert-butyl 3-((tert-butoxycarbonyl)amino)-4-oxobutanoate (6) 7
A solution of oxalyl chloride (2.5 mL, 29.0 mmol) in DCM (42 mL) was cooled to -70 °C and to this was added a solution of DMSO (4.8 mL, 68.0 mmol) in DCM (10 mL) drop wise over a period of 30 minutes. Next, a solution of alcohol intermediate 5 (4.7 g, 17.0 mmol) in DCM (20 mL) was added drop wise over 30 minutes and the reaction was stirred for another 15 minutes at -70 °C. Finally, triehtylamine (15.4 mL, 110.5 mmol) in DCM (42 mL) was added drop wise in 20 minutes after which the reaction was stirred for 1 hour at -70 °C. The reaction mixture was diluted with 400 mL Et 2 O and extracted three times with an aqueous 0.5 M KHSO 4 solution. It was concentrated to approximately half its volume and diluted with another 200 mL Et 2 O, followed by extraction with water and brine. The organic layer was dried over MgSO 4 and concentrated under reduced pressure. The crude aldehyde was subjected to the next step without purification.
(S)-tert-butyl 3-((tert-butoxycarbonyl)amino)pent-4-ynoate (7)
This compound was synthesized using a reported procedure 1 . Dimethyl-2-oxopropylphosphonate (2.76 mL, 20.5 mmol) was added to a suspension of K 2 CO 3 (7.0 g, 51.0 mmol) and p-toluenesulfonylazide (4.0 g, 20.5 mmol) in ACN (255 mL) and the mixture was stirred vigorously for 2 hours. Crude aldehyde 6 (~17.0 mmol) was dissolved in MeOH (50 mL) and this solution was added to the first reaction mixture. Stirring was continued for 14 hours after which the solvents were evaporated under reduced pressure. Residual solids were dissolved in Et 2 O (150 mL) and water (150 mL) and the layers were separated. The organic layer was washed with water and brine, dried over MgSO 4 and concentrated under reduced pressure. The title compound was obtained after purification by column chromatography (DCM isocratic) as a colorless oil (yield: 1.89 g, 7.0 mmol, 41 % 
(S)-tert-butyl 3-aminopent-4-ynoate hydrochloride (8)
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This compound was prepared using a reported procedure for the removal of a Boc group in the presence of a tertbutyl ester 8 . A freshly obtained solution of 4M HCl in dioxane (72 mL) was cooled to 0 °C under argon and this was added to a cooled (0 °C) flask containing compound 7 (930 mg, 3.5 mmol). The ice bath was removed and the mixture was stirred for 30 minutes after which the mixture was concentrated under reduced pressure at room temperature. 
Synthesis of IL-1β-Prg peptides
IL-1β peptides were synthesized on TentaGel® R TRT-His(Trt) Fmoc (Rapp Polymere GmbH; RA1214), a resin preloaded with His(Trt). After synthesis of the peptides (12.5 µmol each), the N-terminus was labeled with Cy5. Cy5 (37.5 µmol, 17.6 mg), PyBOP (37.5 µmol, 19.5 mg) and Et 3 N (75 µmol, 10.5 µL) were dissolved in 100 μL NMP and added to the resin. After shaking overnight, the resin was washed with NMP and subsequently with DCM. The resin was then incubated for 30 minutes with 2 bed volumes of hexafluoroisopropanol:DCM mixture (2:8) to afford DCM-soluble protected IL-1β peptides lacking the C-terminal aspartic acid. After evaporation of solvent under reduced pressure, the solid was dissolved in DCM (10 mL), and PyBOP (50 µmole, 26 mg), triethylamine (150 µmole, 26 µl) and HCl•NH 2 -Asp(OtBu)-Prg 8 (50 µmol, 10 mg) were added. The reaction mixture was stirred at room temperature overnight before concentration in vacuo. The resulting off-white solid was dried overnight under high vacuum.
The peptides were obtained by deprotection using TFA cleavage mixture (95% TFA, 3% H2O, 2% triisopropylsilane) for 2.5 hours. The deprotected polypeptide was precipitated using ice cold diethyl ether:n-pentane (3:1). The precipitated crude product was collected by centrifugation (1000 g, 5 minutes) and washed 3x with cold diethyl ether.
IL-1β-Prg peptides were purified using generic C18-based RP-HPLC method.
General procedure for the conversion of tri-/tetra-peptide aldehydes to their corresponding alkynes
To a solution of Leupeptin (100mg) in 5 ml MeOH was added 50uL dimethyl(1-diazo-2oxopropyl)phosphonate (Ohira-Bestmann reagent, TCI D3546). Then K 2 CO 3 (40 mg) was added. The reaction was stirred overnight. The resulting yellow solution was diluted in water and purified using RP-HPLC. Fluorescence polarization assay of UCHL3 inhibition in presence of Ub-Prg.
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The fluorescence polarization assay was performed as described previously 9 .
Reaction between Ub-Prg and DUBs
General procedure: DUB was diluted in PBS with 5 mM dithiothreitol to a concentration of 1 mg/ml. Ub-Prg was dissolved in DMSO to a concentration of 10 mg/ml, which was then diluted to 1 mg/mL. An equal volume of UbPrg was added to UCHL3, corresponding to a 3-fold molar excess of Ub-Prg. The reaction was allowed to proceed at 37 °C under gentle agitation for 30 minutes after which it was analyzed by LC-MS and/or SDS-PAGE.
To study the effect of a specific inhibitor, it was pre-mixed with the Ub-Prg solution and this mixture was added to the UCHL3. The reaction was the allowed to proceed at 37 °C under gentle agitation for 30 minutes after which it was analyzed by LC-MS and/or SDS-PAGE.
Figure MM14: Reaction of Ub-Prg with UCHL3 (top) before reaction with Ub-Prg (bottom) after reaction with UCHL3
Purification of the complex and analytical data
After successful modification of the DUB the solution was buffer exchanged using Sephadex G25 resin (PD-10, GE Healthcare) to Buffer A (50 mM Tris, pH 7.5, 5% Glycerol). The sample was applied on 6ml Resource Q cartridge using an AKTA Purifier. The complex was eluted using a shallow gradient running from 20 -30% Buffer B (50 mM, pH 7.5; 5% Glycerol; 500 mM NaCl). Resulting fractions were analysed by SDS-PAGE and the appropriate fractions were pooled. 
Reaction of Ub-Prg and UCHL3 in presence of NONOates
Ub-Prg (1 mg/mL, 10 µL) in phosphate buffer (100 mM, pH 7.4) was incubated with 100 mM, 10 mM or 1 mM of diethylenetriamine NONOate (Enzo Life Sciences ALX-430-014), dipropylenetriamine NONOate (Enzo Life Sciences ALX-430-066) or diethylamine NONOate (Sigma-Aldrich D184) for 30 minutes at 37 °C. UCHL3 (1 mg/mL, 10 µL) in phosphate buffer (100 mM, pH 7.4) was then added and the reaction was incubated for 30 minutes at 37 °C prior to analysis by SDS-PAGE.
Alternatively, UCHL3 (1 mg/mL, 10 µL) in phosphate buffer (100 mM, pH 7.4) was incubated with 100 mM, 10 mM or 1 mM of diethylenetriamine NONOate (Enzo Life Sciences ALX-430-014), dipropylenetriamine NONOate (Enzo Life Sciences ALX-430-066) or diethylamine NONOate (Sigma-Aldrich D184) for 30 minutes at 37 °C. UbPrg (1 mg/mL, 10 µL) in phosphate buffer (100 mM, pH 7.4) was then added and the reaction was incubated for 30 minutes at 37 °C prior to analysis by SDS-PAGE.
SDS-PAGE kinetics of the reactions between Ub-Prg, Ub-VME and UCHL3
UCHL3 (1 mg/mL in PBS; 5 µL per timepoint) was incubated with either Ub-Prg (1 mg/mL in PBS + 10% DMSO; 5 µL) or Ub-VME (1 mg/mL in PBS + 10% DMSO; 5 µL) in PBS at 37 °C. One microcentrifuge tube was prepared per timepoint and at the indicated timepoints (see Figure S8 ), the tubes were placed on ice and 4x LDS-sample buffer containing 300 mM DTT was added. The samples were then briefly boiled and stored until analysis by SDS-PAGE at the end of the timecourse.
Acid cleavage of the complex between Ub-Prg and the DUBs
To a solution of Ub-Prg~UCHL3 complex in PBS (3 mg/ml; 10 µL) at room temperature a 3-fold concentrated solution of the tested acid (5 µL) was added to arrive at the final concentration indicated. The reactions were incubated for 3 hours and analyzed by SDS-PAGE chromatography and/or mass spectrometry.
Labeling of overexpressed DUBs in cell lysates
For overexpression of GFP-tagged DUBs in cells, wild type USP14, Otub1, Otub2, Otud1 and POH1 were subcloned from pDEST-cDNA constructs (Addgene) into the eGFP-C1 vector system (Clontech) using the XhoI/EcoRI restriction sites. Mutagenesis of catalytic Cysteines was performed by standard protocols (Stratagene) using the following primers (sites of mutagenesis underlined): USP14-C114S forward-CTT GGT AAC ACT TCT TAC ATG AAT GCC, reverse-GGC ATT CAT GTA AGA AGT GTT ACC AAG; Otub1-C91S forward-CCT GAC GGC AAC TCT TTC TAT CGG GC, reverse-GC CCG ATA GAA AGA GTT GCC GTC AGG; Otub2-C51S forward-GG GAT GGG AAC TCC TTC TAC AGG GCC, reverse-GGC CCT GTA GAA GGA GTT CCC ATC CC. All constructs were verified by DNA sequencing. DNA delivery into MelJuSo cells was performed in 60mm tissue culture plates using Lipofectamine2000 (Invitrogen) according to manufacturer's instructions. 24h following transfection, cells were harvested by scraping in 0.25ml HR lysis buffer, and reactions were incubated for 30 min with agitation at 37C in the absence or presence of the probe (4 µg/reaction). Reactions were stopped by the addition of sample loading buffer supplemented with β-mercaptoethanol, followed by boiling for 10min. Samples were resolved on 4-12% Bis-Tris NU-PAGE Gels (Invitrogen) using MOPS buffer. Probe reactivity was assessed by TAMRA fluorescence scanning as described above. Gels were then transferred onto Nitrocellulose membranes and immunoblotted using rabbit anti-GFP serum 10 and mouse anti-β-actin (Sigma-Aldrich). Immunoblots were visualized using a LICOR Odyssey system. The following fluorescent secondary antibodies purchased from LICOR were used: anti-mouse-680, anti-rabbit-800.
Immobilization of Ub-Prg on CNBr-resin
Ub-Prg (10 mg, 1.2 µmol) or Ubiquitin (10 mg, 1.2 µmol) were immobilized on 500 mg of cyanogen bromide (CNBr)-activated Sepharose 4b resin according to the manufacturer's protocol (GE Healthcare). Spectrophotometric analysis before and after coupling of the ubiquitin derivatives, indicated coupling of either protein to a final loading of 10 mg protein per gram of resin.
Pulldown of UCHL3 from a mixture of UCHL3 and BSA UCHL3 in PBS (4 mg/mL) and bovine serum albumin (4 mg/mL) were mixed in a 1:1 ratio. 50 µL of the mixture was diluted with the indicated amounts of Ub-Prg-modified Sepharose 4b and incubated for 2 hours at 37 °C. As a control Sepharose 4B modified with Ub-76 was included. After incubation, the flowthroughs were analysed by SDS-PAGE.
Washing and retrieval of immobilized UCHL3
UCHL3 and BSA were mixed as above and 100 µL of the above mixture was incubated with 50 mg of the Ub-Prgsepharose at 37 °C for 2 hours. The resin was then washed with 5% SDS in PBS (3 x 500 µL) and water (3 x 500 µL). After washing, the resin was incubated with 10% trifluoroacetic acid (TFA) in water for 3 hours. The TFA and water were removed under reduced pressure followed by lyophilization overnight. The resulting powder was resuspended in Nu-PAGE SDS sample buffer (Invitrogen, 4x concentrate, 100 µL) and boiled for 20 minutes. The insoluble resin-fraction was removed by centrifugation at 14,000 g prior to analysis of the supernatant by SDS-PAGE (right gel below). Pulldown of DUBs from cell lysates 50 mg of the above resin was incubated with EL-4 lysate (1 mL, 3 mg/mL soluble protein in PBS + 10 mM DTT + Roche protease inhibitor tablet) at 37 °C for 3 hours. After elution of the flowthrough, the resin was washed with PBS + 1% Triton X-100 (3 x 10 mL), 2% CHAPS, 8M Urea in PBS (6 x 10 mL) and water (6 x 10 mL). The bound proteins were either eluted off as described above and analysed by SDS-PAGE followed by in-gel digestion, or digested on-bead.
In-gel digestion
Each lane from the Coomassie-stained gel was cut into 10 slices of equal size. The gel pieces were placed in a 0.5-ml tube and washed with 250 µl of water, followed by 15-min dehydration with 100% acetonitrile (ACN). Proteins were reduced with 100 µl 10 mM dithiothreitol (DTT) in 50 mM NH 4 HCO 3 for 1 h at 56°C, followed by dehydration with 100% ACN and incubation in 100 µl 55 mM chloro acetamide in 50 mM NH 4 HCO 3 in the dark. Then, the gel pieces were dehydrated twice with 100 µl 100% ACN, and 20 µl of 0.1 mg/ml trypsin in 50 mM NH 4 HCO 3 was added to each sample, followed by 60-90-min incubation at 4°C. After removal of excess trypsin, samples were incubated in 20 µl of 50 mM NH 4 HCO 3 overnight at 37°C, and the supernatants were transferred to new tubes. Peptides were extracted from the gel pieces with 100 % ACN for 15 min. Supernatants were collected and combined with the ones from the previous step. Samples were dried down in a SpeedVac and reconstituted with 40 µl of 10% formic acid.
On-bead digestion
After the pull-down, the beads were washed 5 times in 1mL 50 mM NH 4 HCO 3 . Immobilized proteins were reduced with dithiothreitol (DTT) at a final concentration of 10 mM at 56 o C for 1 hour. Lysates were alkylated with 55 mM chloroacetamide in 50 mM ammonium bicarbonate for 30 minutes at room temperature in the dark and subsequently dissolved in 8M Urea in 50 mM NH 4 HCO 3 and digested for 4 hours with Lys-C (1:100 w/w). Lysates were then diluted 4-fold to a final concentration of 2M Urea with 50 mM ammonium bicarbonate and digested overnight with Trypsin (1:100 w/w) at 37°C.Tryptic peptides were desalted and labeled in solution with dimethyl reagents as described previously 11 . Light labels were used for the control resin while intermediate label were used for the Propargyl resin. The differentially dimethyl labeled samples were mixed in 1:1 ratio, desalted, dried in vacuo and analyzed by LC-MS/MS.
LC-LTQ-Orbitrap mass spectrometry analysis
Dimethyl labelled samples were analyzed on a nano-LC coupled to an LTQ-Orbitrap Velos (Thermo Scientific, Bremen, Germany). The nano-LC consists of an Agilent 1200 series LC system equipped with a 20 mm ReproSilPur C18-AQ (Dr. Maisch GmbH, Ammerbuch, Germany) trapping column (packed in-house, i.d., 100 μm; resin, 5 μm) and a 400 mm ReproSil-Pur C18-AQ (Dr. Maisch GmbH, Ammerbuch, Germany) analytical column (packed in-house, i.d., 50 μm; resin, 3 μm) arranged in a vented-column configuration. The flow was passively split to 100 nl/min. A 3 hour elution profile consisting of: 0-10 min isocratic solvent A (0.1 M acetic acid) at 5 μL/min for
